 NEW YORK, June 10, 2021 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in June: June 14-18: BIO Digital formerly BIO International Convention. Members of the companys business development team will host one-on-one partnering meetings during the conference. 